MedTrace Logo

Efficacy of CL25216 on Hormonal Balance and Menstrual Health in Women With Primary Dysmenorrhea.

NCT07529561 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-04-14

No results posted yet for this study

Summary

This study is to evaluate the effects of CL25216 on hormonal balance and menstrual health in women with primary dysmenorrhea. Enrolled subjects will receive either CL25216 - 250 mg/day or placebo.

Conditions

  • Primary Dysmenorrhea
  • Menstural Cramps

Interventions

DIETARY_SUPPLEMENT

CL25216

CL25216: 250mg, One capsule a day after breakfast for 84 days.

OTHER

Placebo

One capsule a day after breakfast for 84 days.

Sponsors & Collaborators

  • ApexCPG LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-13
Primary Completion
2026-09-10
Completion
2026-09-10

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07529561 on ClinicalTrials.gov